Completed PHASE2 INTERVENTIONAL 2-arm NCT00079482

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations

Sponsor: Cephalon

Conditions Acute Myeloid Leukemia

Interventions CEP-701 Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy) high-dose cytarabine

Updated 9 times since 2017 Last updated: Jul 19, 2016 Started: Oct 31, 2003 Primary completion: Mar 31, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Myeloid Leukemia and is currently completed. Cephalon leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2022 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ann Arbor, United States , Atlanta, United States , Auckland, New Zealand , Baltimore, United States , Barcelona, Spain , Beech Grove, United States , Bialystok, Poland , Birmingham, United States , Bologna, Italy and 64 more locations